-
Je něco špatně v tomto záznamu ?
Cranberry fruit powder (Flowens™) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study
A. Vidlar, V. Student, J. Vostalova, E. Fromentin, M. Roller, V. Simanek, V. Student,
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
NLK
ProQuest Central
od 1997-02-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-02-01 do Před 1 rokem
- MeSH
- časové faktory MeSH
- dvojitá slepá metoda MeSH
- fytoterapie metody MeSH
- hyperplazie prostaty komplikace patofyziologie terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- močení fyziologie MeSH
- následné studie MeSH
- ovoce * MeSH
- prášky, zásypy, pudry terapeutické užití MeSH
- symptomy dolních močových cest etiologie patofyziologie terapie MeSH
- Vaccinium macrocarpon * MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia increase with age. To date, several medications are available to treat LUTS, including herbal remedies which offer less side effects but lack robust efficacy studies. METHODS: This 6-month, randomized, double-blind, placebo-controlled study aimed at evaluating the dose effect of 250 or 500 mg cranberry powder (Flowens™) on LUTS and uroflowmetry in men over the age of 45. A total of 124 volunteers with PSA levels <2.5 ng/mL and an international prostate symptoms score (IPSS) score ≥8 were recruited and randomized. The primary outcome measure was the IPSS, evaluated at 3 and 6 months. Secondary outcome measures included quality of life, bladder volume (Vol), maximum urinary flow rate (Q max), average urinary flow rate (Q ave), ultrasound-estimated post-void residual urine volume (PVR), serum prostate-specific antigen, selenium, interleukin 6, and C-reactive protein at 6 months. RESULTS: After 6 months, subjects in both Flowens™ groups had a lower IPSS (-3.1 and -4.1 in the 250- and 500-mg groups, p = 0.05 and p < 0.001, respectively) versus the placebo group (-1.5), and a dose-response effect was observed. There were significant differences in Q max, Q ave, PVR, and Vol in the Flowens™ 500-mg group versus baseline (p < 0.05). A dose-dependent effect on Vol was observed, as well as on PVR, for participants with a nonzero PVR. There was no effect on clinical chemistry or hematology markers. CONCLUSIONS: Flowens™ showed a clinically relevant, dose-dependent, and significant reduction in LUTS in men over 45.
Department of Urology University Hospital Olomouc Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17001129
- 003
- CZ-PrNML
- 005
- 20170117124458.0
- 007
- ta
- 008
- 170103s2016 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00345-015-1611-7 $2 doi
- 024 7_
- $a 10.1007/s00345-015-1611-7 $2 doi
- 035 __
- $a (PubMed)26049866
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Vidlar, Ales $u Department of Urology, University Hospital, Olomouc, Czech Republic.
- 245 10
- $a Cranberry fruit powder (Flowens™) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study / $c A. Vidlar, V. Student, J. Vostalova, E. Fromentin, M. Roller, V. Simanek, V. Student,
- 520 9_
- $a BACKGROUND: Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia increase with age. To date, several medications are available to treat LUTS, including herbal remedies which offer less side effects but lack robust efficacy studies. METHODS: This 6-month, randomized, double-blind, placebo-controlled study aimed at evaluating the dose effect of 250 or 500 mg cranberry powder (Flowens™) on LUTS and uroflowmetry in men over the age of 45. A total of 124 volunteers with PSA levels <2.5 ng/mL and an international prostate symptoms score (IPSS) score ≥8 were recruited and randomized. The primary outcome measure was the IPSS, evaluated at 3 and 6 months. Secondary outcome measures included quality of life, bladder volume (Vol), maximum urinary flow rate (Q max), average urinary flow rate (Q ave), ultrasound-estimated post-void residual urine volume (PVR), serum prostate-specific antigen, selenium, interleukin 6, and C-reactive protein at 6 months. RESULTS: After 6 months, subjects in both Flowens™ groups had a lower IPSS (-3.1 and -4.1 in the 250- and 500-mg groups, p = 0.05 and p < 0.001, respectively) versus the placebo group (-1.5), and a dose-response effect was observed. There were significant differences in Q max, Q ave, PVR, and Vol in the Flowens™ 500-mg group versus baseline (p < 0.05). A dose-dependent effect on Vol was observed, as well as on PVR, for participants with a nonzero PVR. There was no effect on clinical chemistry or hematology markers. CONCLUSIONS: Flowens™ showed a clinically relevant, dose-dependent, and significant reduction in LUTS in men over 45.
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a následné studie $7 D005500
- 650 12
- $a ovoce $7 D005638
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a symptomy dolních močových cest $x etiologie $x patofyziologie $x terapie $7 D059411
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a fytoterapie $x metody $7 D008517
- 650 _2
- $a prášky, zásypy, pudry $x terapeutické užití $7 D011208
- 650 _2
- $a hyperplazie prostaty $x komplikace $x patofyziologie $x terapie $7 D011470
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a močení $x fyziologie $7 D014554
- 650 12
- $a Vaccinium macrocarpon $7 D029799
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Student, Vladimir $u Department of Urology, University Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Vostalova, Jitka $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Fromentin, Emilie $u NATUREX-DBS, 375 Huyler Street, South Hackensack, NJ, USA. e.fromentin@naturex.com.
- 700 1_
- $a Roller, Marc $u NATUREX SA, 250 Rue Pierre Bayle, 84911, Avignon, France.
- 700 1_
- $a Simanek, Vilím $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Student, Vladimir $u Department of Urology, University Hospital, Olomouc, Czech Republic.
- 773 0_
- $w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 34, č. 3 (2016), s. 419-24
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26049866 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170103 $b ABA008
- 991 __
- $a 20170117124604 $b ABA008
- 999 __
- $a ok $b bmc $g 1180269 $s 961696
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 34 $c 3 $d 419-24 $e 20150607 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
- LZP __
- $a Pubmed-20170103